Please enable JavaScript.
Coggle requires JavaScript to display documents.
GLP-1 RECEPTOR AGONIST AB2 (CONTRAINDICATIONS (Patient at high risk for…
GLP-1 RECEPTOR AGONIST
CONTRAINDICATIONS
Patient at high risk for pancreatitis
Patients with excessive alcohol use
History of pancretitis
History of pancreatic tumour
History of medullary thyroid cancer or
Multiple endocrine neoplasia syndrome type 2
Patients with GI disorders
DOSING
Exernetide
More than 30ml/min – initialdose is 5 ug
Less than 35ml/min – contraindication
Liraglutide
More than 30ml/min – initiate 0,6 mg max dose
Of 1,8 mg daily
Less than 35ml/min – no adjustment
SIDE EFFECTS
Vomiting
Nausea
Skin reaction
SAFETY PRECAUTIONS
Must discontinue if the rate of
vomitus is between 5-10%
MECHANISM OF ACTION
Their molecules have structural homology
With endogenous GLP-1
DLP-1 agonist are modified
Resistance to the enzymatic cleavage by DPP-4
INDICATIONS
patients with cardiovascular disease
preferable for over weight or obese patients
CLASS
incretin mimetics
